Through screening of the Prestwick Chemical Library, which contains about 1120 FDA-approved drugs, we found that niclosamide targeted AR-V74, reversed resistance of prostate cancer cells to medications targeting the androgen-AR pathway both in vitro and in vivo, and prolonged the survival of mice carrying resistant prostate cancer xenografts4–7. This evidence concerns the gene AR and prostate carcinoma.